Prospects for neurodegenerative and psychiatric disorder drug discovery

Expert Opinion on Drug Discovery

Volumn 6, Issue 5, 2011, Pages 457-463

  Williams, Michael ^a   Enna, S J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimers disease; biomarkers; major depression; neurodegenerative disorders; schizophrenia; translational medicine

Indexed keywords

AGLOMELATINE; AMFEBUTAMONE; ARIPIPERAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DULOXETINE; FLUOXETINE; GSK 37247; HALOPERIDOL; OLANZEPINE; QUETIAPINE; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZIPRASIDONE;

CENTRAL NERVOUS SYSTEM; HUMAN; MENTAL DISEASE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 79955401302     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2011.562497     Document Type: Review

References (26)

1. Klein DF. The loss of serendipity in psychopharmacology. JAMA 2008;299:1063-5 (Pubitemid 351347065)
2. Enna SJ, Williams M. Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Therap 2009;329:404-11
3. Iglehart JK. Prioritizing comparative-effectiveness research - IOM Recommendations. N Engl J Med 2009;361:325-32
4. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatr 2008;192:161-3 (Pubitemid 351347371)
5. Mathew SJ, Charney DS. Publication bias and the efficacy of antidepressants. Am J Psychiatry 2009;166:140-5
6. OCollins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77 (Pubitemid 43358067)
7. Extance A. Alzheimers failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010;9:749-51
8. Woolf CJ. Overcoming obstacles to developing new analgesics. Nat Med 2010;16:1241-7
9. Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 2009;8:541-6
10. Brady LS, Winsky L, Goodman W, et al. NIMH initiatives to facilitate collaborations between industry, academia and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders. Neuropsychopharmacol Rev 2008;34:229-43
11. Wadman W. NIH director wins bid for translational medicine centre. Nature 2010, doi:10.1038/news.2010.650
12. Miller G. Is pharma running out of brainy ideas? Science 2010;329:502-4
13. Nierenberg AA. The perfect storm: CNS drug development in trouble. CNS Spectr 2010;15:282-3
14. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci 2010;12(13):1161-79
15. Horrobin DF. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov 2003;2:151-4 (Pubitemid 37361647)
16. Akil H, Brenner S, Kandel E, et al. The future of psychiatric research: genomes and neural circuits. Science 2010;327:1580-1
17. Flood DG, Marek G, Williams M. Developing predictive CSF Biomarkers - a challenge critical to success in Alzheimers disease and neuropsychiatric translational medicine. Biochem Pharmacol 2011; In press; doi:10.1016/j. bcp.2011.01.021
18. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatr 2010;167:748-51
19. Saddichha S. Disease mongering in psychiatry: is it fact or fiction? World Med Health Policy 2010:2:267-84
20. Moncrieff J. Is psychiatry for sale? An examination of the influence of the pharmaceutical industry on academic and practical psychiatry. Maudsley Discussion Paper 2003;13. Available from: http://www.critpsynet.freeuk.com/ pharmaceuticalindustry.htm
21. Lindner M. Clinical attrition due to biased preclinical assessments of potential efficacy. Pharmacol Ther 2007;115:148-75 (Pubitemid 46992811)
22. Godleee F, Loder E. Missing clinical trial data: setting the record straight. BMJ 2010;341:c4641
23. Lehrer J. Annals of science. The Truth Wears Off. New Yorker, December 13th, 2010. Available from: http://archives. newyorker.com/?i=2010-12-13#folio= 052
24. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003;1003:318-27 (Pubitemid 38083065)
25. Chen G, Twyman R, Manji HK. p11 and gene therapy for severe psychiatric disorders: a practical goal? Sci Transl Med 2010;2:54ps51
26. Bloom FE. Commentary: physician-scientists frustrations fester. Neuropsychopharmacol 2009;34:1-5